<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Ann Hematol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Ann. Hematol</journal-id>
      <journal-title-group>
        <journal-title>Annals of Hematology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0939-5555</issn>
      <issn pub-type="epub">1432-0584</issn>
      <publisher>
        <publisher-name>Springer Berlin Heidelberg</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27766392</article-id>
      <article-id pub-id-type="pmc">5226989</article-id>
      <article-id pub-id-type="publisher-id">2856</article-id>
      <article-id pub-id-type="doi">10.1007/s00277-016-2856-y</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter to the Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>HLA-haploidentical hematopoietic stem cell transplantation with low-dose thymoglobulin GVHD prophylaxis for an adult T cell leukemia/lymphoma patient treated with pretransplant mogamulizumab</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Hirosawa</surname>
            <given-names>Makoto</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Higashi</surname>
            <given-names>Takehiro</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Iwashige</surname>
            <given-names>Atsushi</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yamaguchi</surname>
            <given-names>Takahiro</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Tsukada</surname>
            <given-names>Junichi</given-names>
          </name>
          <address>
            <phone>+81 (93) 691-7435</phone>
            <email>jtsukada@med.uoeh-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1">Hematology, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi, Kitakyushu, 807-8556 Japan </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>21</day>
        <month>10</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>21</day>
        <month>10</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2017</year>
      </pub-date>
      <volume>96</volume>
      <issue>2</issue>
      <fpage>327</fpage>
      <lpage>328</lpage>
      <history>
        <date date-type="received">
          <day>29</day>
          <month>9</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>4</day>
          <month>10</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2016</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer-Verlag Berlin Heidelberg 2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <p>Dear Editor,</p>
    <p>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been considered as standard therapy for aggressive adult T cell leukemia/lymphoma (ATLL) patients to achieve a long-term survival [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Anti-CCR4 monoclonal antibody mogamulizumab (Mog) is the first immunotherapeutic agent targeting ATLL. Since CCR4 is expressed on regulatory T cells (Treg), there is growing concern regarding increased risk of severe and refractory acute graft-versus-host disease (aGVHD) in ATLL patients treated with Mog before allo-HSCT (pretransplant Mog) [<xref ref-type="bibr" rid="CR3">3</xref>&#x2013;<xref ref-type="bibr" rid="CR6">6</xref>].</p>
    <p>We describe a case of an acute-type ATLL patient who underwent HLA-haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) following pretransplant Mog. The interval between the last Mog administration and haplo-PBSCT was 49&#xA0;days. A 65-year-old Japanese male presented with a 2-week history of fatigue, anorexia, and nausea. He was diagnosed as acute-type ATLL with hypercalcemia. His ATLL including abnormal bone lesions was chemorefractory. Therefore, he was further treated with two doses of Mog (1&#xA0;mg/kg weekly for 2&#xA0;weeks). The disease status significantly improved after Mog administration. Unmanipulated haplo-PBSCT was performed from his son (Table <xref rid="Tab1" ref-type="table">1</xref>). The conditioning consisted of fludarabine (25&#xA0;mg/m<sup>2</sup>/day, days &#x2212;8 to &#x2212;4), melphalan (80&#xA0;mg/m<sup>2</sup>, day &#x2212;3), rabbit anti-thymocyte globulin (thymoglobulin; 2.5&#xA0;mg/kg, day &#x2212;2), and TBI (4&#xA0;Gy). Tacrolimus and mycophenolate mofetil were further used for GVHD prophylaxis. Stable and complete donor chimerism was obtained. On day 30, he only developed grade I aGVHD (stage 1 skin rash). One year later, the number of CD4&#x2009;+&#x2009;CD25&#x2009;+&#x2009;CD127-/low Treg cells and CD4&#x2009;+&#x2009;T cells in his PB remained below the normal range (15/&#x3BC;L and 183/&#x3BC;L, respectively), showing delayed T cell reconstitution. He has been in complete remission (CR) without chronic GVHD for 2&#xA0;years.<table-wrap id="Tab1"><label>Table 1</label><caption><p>HLA status of the patient and donor</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Sex</th><th>Relation</th><th>Blood type</th><th>HLA-A</th><th>HLA-B</th><th>HLA-C</th><th>HLA-DR</th></tr></thead><tbody><tr><td>Recipient</td><td>Male</td><td/><td>A+</td><td>0201/2402</td><td>3901/5502</td><td>0702/0102</td><td>1201/0901</td></tr><tr><td>Donor</td><td>Male</td><td>Son</td><td>A+</td><td>0201/0206</td><td>3901/5101</td><td>0702/1402</td><td>1201/0803</td></tr></tbody></table></table-wrap>
</p>
    <p>Low-dose thymoglobulin, in addition to its T cell depleting properties, stimulates the recovery of Treg cells [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. In this regard, Motohashi et al. reported an acute-type ATLL patient who achieved CR following Mog treatment and subsequently received unrelated bone marrow transplantation (uBMT) [<xref ref-type="bibr" rid="CR9">9</xref>]. Two months after the last Mog administration, uBMT was performed from a serologically two antigen (HLA-C and -DR) mismatched donor by using conditioning with 1.25&#xA0;mg/kg of thymoglobulin. As a result, they only observed grade I aGVHD.</p>
    <p>In ATLL, allo-HSCT at disease regression induced by initial treatment has been shown to improve the clinical outcome [<xref ref-type="bibr" rid="CR10">10</xref>]. Pretransplant Mog significantly improved the disease status before haplo-PBSCT. Moreover, a recent nationwide study of ATLL patients with pretransplant Mog in Japan showed that pretransplant Mog with intervals of &lt;50&#xA0;days to allo-HSCT was associated with increased risk of GVHD-related mortality [<xref ref-type="bibr" rid="CR6">6</xref>]. In our case, the interval between pretransplant Mog and haplo-PBSCT was 49&#xA0;days. The nationwide study also pointed out the possibility that in vivo effector T cell depletion with anti-thymocyte globulin contributes to the reduction of severe aGVHD in ATLL patients with pretransplant Mog [<xref ref-type="bibr" rid="CR6">6</xref>]. To our knowledge, our case is the first report of successful prevention of aGVHD with low-dose thymoglobulin in haplo-PBSCT following pretransplant Mog. Low-dose thymoglobulin is an effective option for aGVHD prophylaxis in ATLL patients with pretransplant Mog.</p>
  </body>
  <back>
    <notes notes-type="COI-statement">
      <title>Compliance with ethical standards</title>
      <p>Written informed consent was obtained from the patient for publication.</p>
      <sec id="FPar1">
        <title>Conflict of interest</title>
        <p>The authors declare that they have no conflict of interest.</p>
      </sec>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Choi</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Tanosaki</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Uike</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Utsunomiya</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tomonaga</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Harada</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma: results of prospective trials</article-title>
          <source>Bone Marrow Transplant</source>
          <year>2011</year>
          <volume>46</volume>
          <issue>1</issue>
          <fpage>116</fpage>
          <lpage>118</lpage>
          <pub-id pub-id-type="doi">10.1038/bmt.2010.92</pub-id>
          <pub-id pub-id-type="pmid">20400987</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ishitsuka</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tamura</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma</article-title>
          <source>Lancet Oncol</source>
          <year>2014</year>
          <volume>15</volume>
          <issue>11</issue>
          <fpage>e517</fpage>
          <lpage>e526</lpage>
          <pub-id pub-id-type="doi">10.1016/S1470-2045(14)70202-5</pub-id>
          <pub-id pub-id-type="pmid">25281470</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sugio</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Aoki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ohta</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Saito</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mogamulizumab treatment prior to allogeneic hematopoietic stem cell transplantation induces severe acute graft-versus-host disease</article-title>
          <source>Biol Blood Marrow Transplant</source>
          <year>2016</year>
          <pub-id pub-id-type="pmid">27220263</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haji</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kiyasu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Suehiro</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Toyoda</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tsuda</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Administration of an anti-CC chemokine receptor 4 monoclonal antibody, mogamulizumab, before allogeneic bone marrow transplantation for adult T-cell leukemia/lymphoma</article-title>
          <source>Bone Marrow Transplant</source>
          <year>2016</year>
          <volume>51</volume>
          <issue>3</issue>
          <fpage>432</fpage>
          <lpage>434</lpage>
          <pub-id pub-id-type="doi">10.1038/bmt.2015.254</pub-id>
          <pub-id pub-id-type="pmid">26524267</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Inoue</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Fuji</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tanosaki</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fukuda</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Pretransplant mogamulizumab against ATLL might increase the risk of acute GVHD and non-relapse mortality</article-title>
          <source>Bone Marrow Transplant</source>
          <year>2016</year>
          <volume>51</volume>
          <issue>5</issue>
          <fpage>725</fpage>
          <lpage>727</lpage>
          <pub-id pub-id-type="doi">10.1038/bmt.2015.315</pub-id>
          <pub-id pub-id-type="pmid">26691420</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fuji</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Inoue</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Utsunomiya</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Moriuchi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Uchimaru</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality</article-title>
          <source>J Clin Oncol</source>
          <year>2016</year>
          <pub-id pub-id-type="pmid">27507878</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lopez</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Clarkson</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Albin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sayegh</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Najafian</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>A novel mechanism of action for anti-thymocyte globulin: induction of CD4&#x2009;+&#x2009;CD25&#x2009;+&#x2009;Foxp3+ regulatory T cells</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2006</year>
          <volume>17</volume>
          <issue>10</issue>
          <fpage>2844</fpage>
          <lpage>2853</lpage>
          <pub-id pub-id-type="doi">10.1681/ASN.2006050422</pub-id>
          <pub-id pub-id-type="pmid">16914538</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feng</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Kajigaya</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Solomou</surname>
              <given-names>EE</given-names>
            </name>
            <name>
              <surname>Keyvanfar</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Raghavachari</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Rabbit ATG but not horse ATG promotes expansion of functional CD4&#x2009;+&#x2009;CD25highFOXP3+ regulatory T cells in vitro</article-title>
          <source>Blood</source>
          <year>2008</year>
          <volume>111</volume>
          <issue>7</issue>
          <fpage>3675</fpage>
          <lpage>3683</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2008-01-130146</pub-id>
          <pub-id pub-id-type="pmid">18250226</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Motohashi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kishimoto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Numata</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nakajima</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tachibana</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Successful treatment of a patient with adult T cell leukemia/lymphoma using anti-CC chemokine receptor 4 monoclonal antibody mogamulizumab followed by allogeneic hematopoietic stem cell transplantation</article-title>
          <source>Int J Hematol</source>
          <year>2013</year>
          <volume>98</volume>
          <issue>2</issue>
          <fpage>258</fpage>
          <lpage>260</lpage>
          <pub-id pub-id-type="doi">10.1007/s12185-013-1387-8</pub-id>
          <pub-id pub-id-type="pmid">23801427</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fuji</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fujiwara</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nakano</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Wake</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Inoue</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Fukuda</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma</article-title>
          <source>Bone Marrow Transplant</source>
          <year>2016</year>
          <volume>51</volume>
          <issue>2</issue>
          <fpage>205</fpage>
          <lpage>211</lpage>
          <pub-id pub-id-type="doi">10.1038/bmt.2015.265</pub-id>
          <pub-id pub-id-type="pmid">26524263</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
